MSD announced on January 5 that Xinruilai®, the world's first and currently the only [1] breakthrough therapy activator signaling inhibitor, has been approved by the China National Drug Administration and is suitable for treating adult patients with pulmonary hypertension with WHO functional grade II-III to improve patients' exercise capacity and WHO functional rating [2]. ASI is a novel biological agent for the treatment of PAH causes. This approval is based on research data from the phase III clinical trial STELLAR.

MSD announced on January 5 that Xinruilai®, the world's first and currently the only [1] breakthrough therapy activator signaling inhibitor, has been approved by the China National Drug Administration and is suitable for treating adult patients with pulmonary hypertension with WHO functional grade II-III to improve patients' exercise capacity and WHO functional rating [2]. ASI is a novel biological agent for the treatment of PAH causes. This approval is based on research data from the phase III clinical trial STELLAR.